ALPK1 inhibitor BI-4286
Using suitable model systems, how would you propose to demonstrate and validate the role of ALPK1 in defined disease indications?
With the goal to better understand the mechanistic role of ALPK1 signaling in disease pathology outside of infectious diseases, we now share a well-characterized small molecule inhibitor of ALPK1, BI-4286 to stimulate novel disease hypotheses.
Successful applicants will receive the previously unpublished and highly potent and selective ALPK1 inhibitor BI-4286 free of charge in the amount required for in vitro and in vivo experiments together with comprehensive information on the molecule. Funding of up to 300,000 euros is available for selected proposals that would be jointly pursued as part of a partnership with scientists from Boehringer Ingelheim.
We look forward to receiving your innovative research proposals in alignment with our collaborative discovery research priorities. To have a chance to collaborate on groundbreaking research, submit your proposals no later than March 10, 2026, 11:59 pm PST.
